Structure and functional properties of lipoprotein lipase.
Explore the source record for details and available documents.
Amino Acid Sequence↗
Biomedical subjects
W J McConathy
Publications and source records attributed to W J McConathy.
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.
In this study we have examined effects of synthetic polypeptide fragments of apoC-III on the kinetic properties of lipoprotein lipase (LPL) activity. Based on the loss of 79% of LPL-inhibitory activity after CNBr cleavage at the N-terminal portion of apoC-III and a systematic search for synthetic peptides with LPL-inhibitory activity spanning the apoC-III sequence, we concluded that the N-terminal domain is the most important in the modulation of LPL activity. In addition, there are multiple attachment sites in apoC-III for its interaction with LPL and these sites reside in the hydrophilic sequences of apoC-III. Probably for this reason the intact apo-CIII exhibited higher inhibitory potential than its peptide components. Based on the deduced inhibition constants derived for the synthetic apoC-III1-79 we concluded that apoC-III is likely to exhibit a physiological role in regulating LPL activity since the derived dissociation constants for the LPL-apoC-III interaction are within the physiological concentration range of plasma apoC-III. In addition, as the synthetic apoC-III1-79 lacks the carbohydrate moiety, we also concluded that the presence of the oligosaccharide in native apoC-III is not essential for its inhibitory activity on LPL. The fact that the I50 (concentration for inhibition of LPL at 50% activity) decreases for apoC-III-1 when assayed in the presence of apoC-II indicated that the activator actually caused an increased affinity between LPL and apoC-III and demonstrated that apoC-III does not compete for the activator site of apoC-II.
Amino Acid Sequence↗
Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins.
Recombinant DNA-derived apolipoprotein(a) was used to demonstrate that the apo(a) moiety of lipoprotein(a) (Lp(a)) is responsible for the binding of Lp(a) to other apolipoprotein B-containing lipoproteins (apoB-Lp) including LDL2, a subclass of low density lipoproteins (d = 1.030-1.063 g/ml). The r-apo(a).LDL2 complexes exhibited the same binding constant as Lp(a).LDL2 (10(-8) M). Treatment of either recombinant apo(a) or Lp(a) with a reducing agent destroyed binding activity. A synthetic polypeptide corresponding to a portion of apo(a)'s kringle-4 inhibited the binding (K1 = 1.9 x 10(-4) M) of LDL2 to Lp(a). Therefore, we concluded that binding to apoB-Lp was mediated by the kringle-4-like domains on apo(a). Using ligand chromatography which can detect complexes having a KD as low as 10(-2) M, we demonstrated the binding of plasminogen to apoB-Lp. Like Lp(a), binding of plasminogen to apoB-Lp was mediated by the kringle domain(s). The differences in binding affinity may be due to amino acid substitutions in the kringle-4-like domain. In most of the kringle-4-like domains of apo(a), the aspartic residue critical for binding to lysine was substituted by valine. Consistent with this substitution, we found that L-proline and hydroxyproline, but not L-lysine, inhibited the binding of LDL2 to apo(a). Inhibition by L-proline could be reversed in the binding studies by increasing the amount of apo(a); and L-proline-Sepharose bound plasma Lp(a), suggesting that L-proline acted as a ligand for the kringle-4-like domain(s) of apo(a) involved in the binding of apoB-Lp. The binding of apo(a) to proline and hydroxyproline could be responsible for the binding of apo(a) to the subendothelial extracellular matrix, i.e. domains of proteins rich in proline or hydroxyproline (e.g. collagen and elastin).
Amino Acids↗
Lp(a) interactions.
In this report, we have summarized our recent studies on lipoprotein(a) (Lp(a)) and its interactions with apolipoprotein B-containing lipoproteins (ApoB-Lp). These findings implicate the kringle-4-like domains of Apo(a) in the binding of Lp(a) to other ApoB-Lp and point to proline as important in this interaction. Other studies have indicated that Lp(a) interacts with the subendothelial extracellular matrix (ECM) and that Lp(a) is inversely related to plasma triglycerides. Since Apo(a) also has an affinity for ApoB-Lp, enhanced binding of Apo(a) to the arterial wall could increase the accumulation of LDL in the matrix and thus promote the development of cardiovascular disease.
Apolipoproteins A↗
Possible role of macrophages in regression of atherosclerosis.
Explore the source record for details and available documents.
Animals↗
Afibrinogenemia and hypobetalipoproteinemia in a kindred.
A 3-year-old boy with minor bleeding problems had no plasma fibrinogen measured by both clottable assay and immuno-precipitation. Low normal fibrinogen levels were present in the mother and father. Markedly decreased plasma cholesterol and apolipoprotein B levels were found in the father, proband's brother, and the paternal side of the kindred. The proband and his mother had normal plasma total cholesterol and apolipoprotein B levels. These findings are compatible with autosomal dominant transmission of hypobetalipoproteinemia and autosomal recessive transmission of afibrinogenemia. Two members of the father's family had plasma cholesterol levels below the fifth percentile but elevated levels of fibrinogen (6.0 and 4.4 g/L). Both have symptomatic coronary heart disease. Finding coronary heart disease with very low cholesterol but elevated fibrinogen levels is consistent with fibrinogen levels being an independent risk factor for coronary heart disease.
Adult↗
C-terminal domain of apolipoprotein CII as both activator and competitive inhibitor of lipoprotein lipase.
In this study we have prepared peptides of the C-terminal domain of apolipoprotein CII (ApoCII) by a solid-peptide-synthesis technique and demonstrated that the C-terminal tetrapeptide, Lys-Gly-Glu-Glu, represents an inhibitor of lipoprotein lipase. The tetrapeptide not only inhibits the basal activity of lipoprotein lipase, but also blocks the activation effect of native ApoCII. The lengthening of this tetrapeptide resulted in a corresponding increase in affinity for lipoprotein lipase. This suggested that amino acids other than those of the C-terminal tetrapeptide also contribute to the binding affinity of ApoCII for lipoprotein lipase. On the basis of an essential requirement of the ApoCII terminal domain for binding to lipoprotein lipase, we suggest that the initial interaction of ApoCII, mediated via the C-terminal tetrapeptide, promotes the proper alignment of ApoCII with lipoprotein lipase, followed by the weak interaction of the ApoCII activator domain with the lipoprotein lipase activator site, enhancing the lipolysis process.
Amino Acid Sequence↗
Lipoprotein(a) binding to other apolipoprotein B containing lipoproteins.
A method combining ligand dot blotting and digital imaging was used to determine the apparent dissociation constant (KD) for the binding of lipoprotein(a) to low-density lipoproteins (Lp(a)-LDL2). By use of this approach, the KD for the Lp(a)-LDL2 complex was shown to be in the nanomolar range [(1.05 +/- 0.21) x 10(-8) M, n = 4]. The Lp(a)-LDL2 interaction was both hydrophobic and ionic; however, hydrophobic forces predominated because the interaction was demonstrable at high salt concentration (greater than 2 M NaCl), while no complex was detectable at low salt concentration (less than 0.08 M NaCl). Consistent with the hydrophobic nature of this interaction, the Lp(a)-LDL2 complex was stable over a wide pH range (4-10). Plasminogen did not compete with Lp(a) binding to LDL2 even at a 2.2 X 10(3) molar excess of plasminogen over the LDL2 concentration. The only component identified in plasma and serum that inhibited the binding of LDL2 to Lp(a) was apolipoprotein B containing lipoproteins (apoB-Lp). These studies indicate that the Lp(a)-LDL2 complex could exist in plasma. In fact, up to 72% of purified Lp(a) added to an Lp(a)-negative hypertriglyceridemic plasma floated with apoB-Lp (d less than 1.063 g/mL) following ultracentrifugation, whereas only 9% of the purified Lp(a) added to the apoB-Lp-free 1.12 g/mL infranate floated at d less than 1.063 g/mL. The formation of a complex of Lp(a) with apoB-Lp could increase the amount of cholesterol ester bound per cellular receptor, e.g., LDL receptor, and thus potentially accelerate cholesterol removal from the vascular compartment.
Animals↗
Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.
Lp(a) lipoprotein purified from human plasma bound with high affinity to isolated bovine LDL receptors on nitrocellulose blots and in a solid-phase assay. Lp(a) also competed with 125I-LDL for binding to human LDL receptors in intact fibroblasts. Binding led to cellular uptake of Lp(a) with subsequent stimulation of cholesterol esterification. After intravenous injection, human Lp(a) was cleared slowly from the plasma of normal mice. The clearance was markedly accelerated in transgenic mice that expressed large amounts of LDL receptors. We conclude that the covalent attachment of apo(a) to apo B-100 in Lp(a) does not interfere markedly with the ability of apo B-100 to bind to the LDL receptor and that this receptor has the potential to play a major role in clearance of Lp(a) from the circulation of intact humans.
Adult↗
Lp(a) and plasma triglyceride-rich lipoproteins.
Based on our studies showing an interaction between Lp(a) and ApoB-containing lipoproteins (ApoB-Lp) and the observation that the interacting ApoB-Lp were somewhat enriched in triglyceride (TG), we have initiated studies to explore this potential relationship of Lp(a) and TG-rich lipoproteins. In exploring Lp(a)'s incidence in hypertriglyceridemic subjects, we found a significantly reduced incidence (31%, p less than 0.05) of Lp(a) levels greater than 9 mg/ml when compared to both normolipidemic (61%) and subjects with coronary heart disease (49%). Analyses of a second group of hypertriglyceridemic subjects (n = 68) demonstrated that only 15% of subjects with TG greater than 400 mg/dl (n = 20) had levels of Lp(a) greater than 9 mg/dl while 52% of those with TG levels less than 400 mg/dl (n = 48) had this level of detectable Lp(a). These studies point to an inverse relationship between plasma TG and Lp(a) levels.
Coronary Disease↗
Inhibition of lipoprotein lipase by the receptor-binding domain of apolipoprotein E.
A synthetic peptide (residues 139-153) corresponding to the receptor-binding domain of apolipoprotein E (ApoE) was tested for lipoprotein lipase (LPL) inhibitory properties. In systems using both natural and synthetic substrates, inhibition of LPL was observed. Using the synthetic substrate, 50% inhibition was observed at 50 microM while high concentrations completely inhibited LPL activity. These studies suggest an additional functional role for the receptor-binding domain of ApoE-modulation of LPL activity.
Animals↗
Cholesterol crystal uptake and metabolism by P388D1 macrophages.
Cholesterol monohydrate crystals are frequently detected in intermediate and advanced atherosclerotic lesions. Little is known regarding mobilization of this molecular form of cholesterol into metabolically active pools. To study a potential mechanism for mobilization of crystalline cholesterol, we examined its uptake by a mouse macrophage cell line (P388D1). Crystals were overlayered on a P388D1 cell monolayer maintained in a serum-free medium. Following incubation, the monolayer was washed, and the cells were harvested and analyzed for crystal internalization. By transmission electron microscopy, crystals were found intracellularly surrounded by a bilayer membrane. Analyses of the cellular cholesterol ester content by gas-liquid chromatography and esterification of [14C]cholesterol indicated the conversion of crystalline cholesterol to cholesterol esters. This pathway for solubilization of cholesterol crystals by macrophages could play an important role in the regression of atherosclerotic lesions.
Animals↗
Plasminogen polymorphism in swine.
1. Plasminogen polymorphism in swine (Sus scrofa) plasma was demonstrated by immunoblotting. 2. Eleven plasminogen phenotypic patterns, including a null pattern, were detected. 3. The null pattern was associated with extremely low plasma triglyceride and increased unesterified cholesterol levels. 4. Changes in plasminogen polymorphic patterns from the fetal to neonate status were observed after nursing commenced.
Animals↗
Lipids and apolipoprotein profiles in men with aneurysmal and stenosing aorto-iliac atherosclerosis.
The plasma lipids, lipoproteins and apolipoproteins have been compared in two groups of men with aorto-iliac atherosclerosis: Aneurysmal disease (n = 42) and stenosing disease (n = 86). The mean age of the men aneurysmal disease was 67.5 +/- 5.8 years and the mean age of the men with stenosing disease was 65.0 +/- 6.1 years: There was no significant different in body mass indices or smoking habits between the groups. The patients with aneurysmal disease had lower levels of plasma cholesterol than patients with stenosing disease (5.53 +/- 1.17 versus 6.11 +/- 1.20 mmol/L, P less than 0.05), but carried more cholesterol in VLDL compared to patients with stenosing disease (1.00 +/- 0.90 versus 0.60 +/- 65 mmol/L, P less than 0.05). Significantly lower concentration of apolipoprotein AI and HDL-cholesterol in patients with aneurysmal disease (ApoAI 1.01 +/- 0.31 versus 1.18 +/- 0.31 mmol/L, P less than 0.02, HDL 0.93 +/- 0.53 versus 1.13 +/- 0.34, P less than 0.05) was another characteristic difference between these two groups of patients with peripheral arterial disease. Otherwise, there were no obvious differences in the levels of plasma triglyceride, VLDL-triglyceride, LDL-cholesterol, and apolipoproteins B, C-III and E between the two groups. Although lipid and apolipoprotein profiles may not discriminate between aneurysmal and stenosing disease, different types of lipoprotein particles may contribute to the atherosclerotic process characterising both diseases.
Aged↗
Separation of swine plasma LDL from Lpb2/3 heterozygotes into two apoB allelic haplotypes, Lpb2 and Lpb3, with apoB epitope specific antibodies.
Studies were performed to investigate the separation of Lpb (lipoprotein B) species present in plasma of heterozygous swine bearing the Lpb2 and Lpb3 apoB mutant genes. Low density lipoprotein (LDL) fractions from Lpb2/2 and Lpb3/3 homozygotes were coupled to a matrix and used to isolate affinity-purified antibodies anti-Lpb2 and anti-Lpb3 from swine alloimmune sera, one with specificity for the Lpb2 epitope(s) and the other for Lpb3. These antibodies in turn were used to construct two immunosorbers, anti-Lpb2 and anti-Lpb3 Sepharose columns. To separate the two Lpb haplotype populations present in LDL, a density gradient ultracentrifuge subfraction (d 1.032-1.043 g/ml) obtained from Lpb2/3 heterozygous pigs was applied to the specific immunosorbers. The retained fraction from the anti-Lpb2 column reacted in the double immunodiffusion test with anti-Lpb2 and anti-Lpb13 immune sera but not with either anti-Lpb3 or anti-Lpb12, while the unretained fractions reacted with anti-Lpb3 and anti-Lpb12 but not with either anti-Lpb2 or anti-Lpb13. The reaction patterns obtained with the two sets of alloimmune sera indicate the existence of two separate lipoprotein populations in LDL: one lipoprotein carrying the Lpb2 and Lpb13 epitopes corresponding to the Lpb2 apoB allele, and the other carrying the Lpb3 and Lpb12 allotypes specified by the Lpb2 gene. Immunoblotting with anti-Lpb2 and anti-Lpb3 and silver staining showed that the epitopes of both isolated LDL subpopulations are associated with apoB-100. Neutral lipid analyses showed no differences between the isolated Lpb2 and Lpb3 lipoprotein species from the Lpb2/3 heterozygotes. These studies demonstrate that plasma LDL subfractions from Lpb heterozygous swine can be separated into two haplotype populations, each corresponding to the product of one apoB gene, and reveal a new insight into the phenotypic expression of plasma LDL, and the LDL phenotype-genotype relationship. Furthermore, this approach will facilitate studies on metabolic differences of two structurally distinct LDL, unaffected by in vitro manipulation, exposed to the metabolic milieu of one individual.
Alleles↗
Tissue distribution of [3H]cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs.
The sites of tissue uptake of human lipoprotein(a) (Lp(a] were studied in rats using [3H]cholesteryl linoleyl ether [( 3H]CLE) as a marker. Since rat plasma has no cholesteryl ester transfer activity, the amount of label in various tissues should reflect the quantitative uptake of Lp(a). Isolated Lp(a) was labeled with [3H]CLE by incubation overnight of Lp(a), a source of cholesteryl ester transfer activity (1.23 g/ml infranate of human plasma), and [3H]CLE-labeled Intralipid. Following labeling, the homogeneity and integrity of Lp(a) was shown by agarose electrophoresis and immunoblotting. Intact Lp(a) was injected via the tail vein of rats (120-170 g, n = 4 at each time point), and tissues were collected at various times thereafter (4-48 h). The disappearance curve of [3H]CLE-labeled Lp(a) from rat plasma was bimodal and had an initial rapid t1/2 of 1.8 h followed by a slower component, t1/2 = 13.3 h. Tissue uptake at all sampling times was greatest in liver (28.5% at 48 h of total dpm injected), followed by the intestine (9-12%), with less than 3% uptake by spleen. The small intestine was divided into four segments, and while the 3H radioactivity was similar in the proximal segments, a time-related increase in [3H]CLE was seen in its most distal portion. These studies indicate that the tissue sites of degradation in the rat of human Lp(a) are similar to human low-density lipoproteins (LDL); the increase in label in the distal portion of the small intestine with time may represent [3H]CLE excreted through the bile and absorbed by the mucosal cells.
Animals↗
Interactions of low density lipoprotein2 and other apolipoprotein B-containing lipoproteins with lipoprotein(a).
Studies were undertaken to investigate potential interactions among plasma lipoproteins. Techniques used were low density lipoprotein2 (LDL2)-ligand blotting of plasma lipoproteins separated by nondenaturing 2.5-15% gradient gel electrophoresis, ligand binding of plasma lipoproteins by affinity chromatography with either LDL2 or lipoprotein(a) (Lp(a)) as ligands, and agarose lipoprotein electrophoresis. Ligand blotting showed that LDL2 can bind to Lp(a). When apolipoprotein(a) was removed from Lp(a) by reduction and ultracentrifugation, no interaction between LDL2 and reduced Lp(a) was detected by ligand blotting. Ligand binding showed that LDL2-Sepharose 4B columns bound plasma lipoproteins containing apolipoproteins(a), B, and other apolipoproteins. The Lp(a)-Sepharose column bound lipoproteins containing apolipoprotein B and other apolipoproteins. Furthermore, the Lp(a) ligand column bound more lipoprotein lipid than the LDL2 ligand column, with the Lp(a) ligand column having a greater affinity for triglyceride-rich lipoproteins. Lipoprotein electrophoresis of a mixture of LDL2 and Lp(a) demonstrated a single band with a mobility intermediate between that of LDL2 and Lp(a). Chemical modification of the lysine residues of apolipoprotein B (apoB) by either acetylation or acetoacetylation prevented or diminished the interaction of LDL2 with Lp(a), as shown by both agarose electrophoresis and ligand blotting using modified LDL2. Moreover, removal of the acetoacetyl group from the lysine residues of apoB by hydroxylamine reestablished the interaction of LDL2 with Lp(a). On the other hand, blocking of--SH groups of apoB by iodoacetamide failed to show any effect on the interaction between LDL2 and Lp(a). Based on these observations, it was concluded that Lp(a) interacts with LDL2 and other apoB-containing lipoproteins which are enriched in triglyceride; this interaction is due to the presence of apolipoprotein(a) and involves lysine residues of apoB interacting with the plasminogen-like domains (kringle 4) of apolipoprotein(a). Such results suggest that Lp(a) may be involved in triglyceride-rich lipoprotein metabolism, could form transient associations with apoB-containing lipoproteins in the vascular compartment, and alter the intake by the high affinity apoB, E receptor pathway.
Apolipoproteins B↗
Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias.
Explore the source record for details and available documents.
Adolescent↗